A study of AZD3514 for prostate cancer that has spread and is no longer responding to hormone therapy

Cancer type:

Prostate cancer




Phase 1

This study looked at a drug called AZD3514 for prostate cancer. 

It was for men with prostate cancer that had spread to another part of the body and was no longer responding to hormone therapy.

More about this trial

Doctors use hormone therapy to treat prostate cancer. This can keep it under control for long periods of time.
But hormone therapy can stop working and researchers are looking for other treatments for prostate cancer when this happens.
In this study, they looked at a drug called AZD3514.
Prostate cancer needs the hormone testosterone Open a glossary item to grow. The testosterone locks into receptors on the cancer cells. AZD3514 works by breaking down these receptors so that testosterone can’t tell the prostate cancer cells to grow.
The aims of the study were to:
  • find the highest safe dose of AZD3514
  • see if it slows the growth of prostate cancer that is no longer responding to hormone therapy
  • learn more about the side effects
  • find out more about AZD3514 and what happened to it in the body
  • see if it was safe to have AZD3514 with a drug called abiraterone

Summary of results

The study team found that AZD3514 worked reasonably well when hormone treatment had stopped working. But the side effects of feeling and being sick were a considerable concern.
This study closed in 2012 and these results were published in 2015.
About the trial
This summary combines the results of 2 studies of AZD3514. 
Both studies were a phase 1 study. A total 70 men took part in both studies. 8 of these men had AZD3514 with abiraterone. 
The first few people had a low dose of AZD3514. The next few had a higher dose and so on until the highest safe dose was found. 
Overall the best dose of AZD3514 was below 2g twice a day.
The most common side effects were:
  • feeling sick 
  • being sick
  • tiredness
  • lack of energy
  • loss of appetite
  • indigestion
  • diarrhoea
  • constipation
Of the 70 men, the PSA blood level of 9 men had gone down by half (50%) or more. 
At 6 months, 30 men had no sign of their cancer getting worse.
At a year, 15 men had no sign of their cancer getting worse. 
The team concluded that the highest safe dose of AZD3514 did work reasonably well. But the side effects of this dose especially feeling and being sick made it unacceptable as a treatment. 
Although the side effects mean that they don’t recommend AZD3514 as a treatment, they have learnt that this type of drug can work. And that further research into related drugs that don’t cause such severe side effects is deserved.
Where we got this information from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr T. Elliott

Supported by

Experimental Cancer Medicine Centre (ECMC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think